<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-041880</identifier>
<setSpec>0001-7310</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Lentigo maligna treated with 5% imiquimod cream</dc:title>
<dc:description xml:lang="en">Lentigo maligna (LM) is considered to be an in-situ stage of lentigo maligna melanoma. Clinically, it presents as a pigmented macule, irregular in shape and tone. 30 % to 35 % of untreated lentigo malignas can progress into lentigo maligna melanoma. The treatment of choice for this pathology is surgical excision with margins of 0.5 cm. of clinically normal skin around the lesion, or Mohs microsurgery. Imiquimod is a topical immunomodulator that stimulates both acquired and innate immunity. We present the case of a patient with LM, treated with 5 % imiquimod cream, with an excellent therapeutic response</dc:description>
<dc:creator>Vera, Ángel</dc:creator>
<dc:creator>Ojeda, Antonio</dc:creator>
<dc:creator>Martín, Trinidad</dc:creator>
<dc:creator>Martínez, Silvestre</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">El lentigo maligno (LM) se considera el estadio in situ del lentigo maligno melanoma. Se presenta clínicamente como una mácula pigmentada de forma y tonalidad irregulares. Del 30 al 35 % de los lentigos malignos no tratados pueden progresar a un lentigo maligno melanoma. El tratamiento de elección de esta patología es la escisión quirúrgica con márgenes de 0,5 cm de piel clínicamente normal alrededor de la lesión o la microcirugía de Mohs. El imiquimod es un inmunomodulador tópico que estimula tanto la inmunidad adquirida como la innata. Presentamos el caso de una paciente con LM tratado con el imiquimod en crema al 5 % con excelente respuesta terapéutica</dc:description>
<dc:source>Actas Dermosifiliogr;96(10): 700-702, dic. 2005. ilus</dc:source>
<dc:identifier>ibc-041880</dc:identifier>
<dc:title xml:lang="es">Lentigo maligno tratado con crema de imiquimod al 5 %</dc:title>
<dc:subject>^d7295^s22021</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d31401^s22067</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d31401^s22016</dc:subject>
<dc:subject>^d8713^s22010</dc:subject>
<dc:subject>^d8714^s22057</dc:subject>
<dc:subject>^d8713^s22063</dc:subject>
<dc:subject>^d22721^s22057</dc:subject>
<dc:subject>^d27905^s22078</dc:subject>
<dc:subject>^d27905^s22000</dc:subject>
<dc:subject>^d27905^s22044</dc:subject>
<dc:subject>^d29051^s22045</dc:subject>
<dc:subject>^d9062</dc:subject>
<dc:subject>^d27905^s22073</dc:subject>
<dc:type>article</dc:type>
<dc:date>200512</dc:date>
</metadata>
</record>
</ibecs-document>
